利拉鲁肽联合二甲双胍在2型糖尿病患者中的防治效果及对机体免疫的影响研究

摘要

Objective :To analyze the effects of liraglutide combined with metformin on the immune response in patients with type 2 diabetes mellitus .Methods :150 patients with type 2 diabetes mellitus were randomly divided into experimental group and control group according to the order of admission ,75 cases in each group .The control group was treated with metformin ,and the treatment group was treated with liraglutide combined with metformin . Statistical analysis was performed using SPSS20 .0 statistical software .The clinical effects ,average body mass in-dex ,blood glucose level (2-hour postprandial blood glucose ,glycosylated hemoglobin ,fasting blood glucose) ,im-munoglobulin level (IgA ,IgG ,IgM) and the incidence of adverse reactions such as parameters .Results:① There was no significant difference in body mass index (BMI) ,2-hour postprandial blood glucose ,glycosylated hemoglo-bin ,fasting blood glucose ,IgA ,IgG and IgM levels between the two groups before treatment (P>0 .05) .After treatment ,(P<0 .05) .The average body mass index (BMI) ,2-hour postprandial blood glucose ,glycosylated he-moglobin (HbA1c) and fasting blood glucose were significantly higher in the experimental group than those in the control group (P< 0 .05) .The total effective rate of the experimental group was 94 .67% (71/75) ,the total effec-tive rate of the control group was 77 .33% (58/75) ,the total effective rate of the experimental group was much higher than the control group (P< 0 .05 );③ The adverse reaction rate was 4 .00% (3/75) in the experimental group and 5 .33% (4/75) in the control group .There was no significant difference in adverse reactions between the two groups (P>0 .05) .Conclusion :The efficacy of liraglutide combined with metformin in the treatment of type 2 diabetes mellitus is significant ,and at the same time ,it can effectively improve the immune function .%目的:探讨利拉鲁肽联合二甲双胍对2型糖尿病患者中的防治效果及对机体免疫的影响.方法:将150例2型糖尿病患者按入院顺序随机分为观察组与对照组,每组75例.对照组应用二甲双胍治疗,观察组应用利拉鲁肽联合二甲双胍治疗.分析两组患者治疗15周后临床治疗效果、平均体质指数、血糖水平(餐后2h血糖、糖化血红蛋白、空腹血糖)、免疫球蛋白水平(IgA、IgG、IgM)以及不良反应发生率等指标.结果:①治疗前,两组患者的平均体质指数、餐后2h血糖、糖化血红蛋白、空腹血糖、IgA、IgG、IgM等比较无统计学意义(P>0.05);治疗后,观察组患者IgA、IgG水平显著低于对照组、IgM水平显著高于对照组(P<0.05),观察组患者平均体质指数、餐后2h血糖、糖化血红蛋白、空腹血糖水平显著优于对照组(P<0.05);②观察组治疗总有效率为94.67%(71/75),对照组治疗总有效率为77.33%(58/75),观察组治疗总有效率明显高于对照组(P<0.05);③观察组不良反应发生率为4.00%(3/75),对照组不良反应发生率为5.33%(4/75),两组患者不良反应发生率比较无统计学意义(P>0.05).结论:利拉鲁肽联合二甲双胍在2型糖尿病患者中的防治效果显著,能有效提高机体免疫功能.